3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00077181
Recruitment Status : Completed
First Posted : February 11, 2004
Last Update Posted : January 24, 2013
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : July 2008
  Study Completion Date : No date given